Evidence map›Paper›PMID 24776984›Full record

ArticleBioengineered

Human leukemia inhibitory factor produced by the ExpressTec method from rice (Oryza sativa L.) is active in human neural stem cells and mouse induced pluripotent stem cells.

Randall Alfano, Bradford A Youngblood, Deshui Zhang, Ning Huang, Clinton C MacDonald

Open access · goldAbstract read
In one paragraph

Article in Bioengineered. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The increasing value of plant-made proteins.Current opinion in biotechnology · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Randall AlfanoInVitria; Fort Collins, CO USA.
Bradford A YoungbloodDepartment of Cell Biology & Biochemistry; Texas Tech University Health Sciences Center; Lubbock, TX USA.
Deshui ZhangVentria Bioscience Inc; Fort Collins, CO USA.
Ning HuangVentria Bioscience Inc; Fort Collins, CO USA.
Clinton C MacDonaldDepartment of Cell Biology & Biochemistry; Texas Tech University Health Sciences Center; Lubbock, TX USA.
Ventria Bioscience (United States) · USLubbock Christian University · USMembrane Protective Technologies (United States) · USTexas Tech University · US

Funding

MRNA PROCESSING IN REPRODUCTION &FERTILIZATIONR01HD037109 · NICHD · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · PI MACDONALD, CLINTON C · 1999 to 2015
$3.3M
NICHD NIH HHS R01 HD037109NICHD NIH HHS R01HD037109
6 · The paper itself

Abstract

Stem cell-based therapy has the potential to treat an array of human diseases. However, to study the therapeutic potential and safety of these cells, a scalable cell culture medium is needed that is free of human or bovine-derived serum proteins. Thus, cost-effective recombinant serum proteins and cytokines are needed to produce such mediums. One such cytokine, leukemia inhibitory factor (LIF), has been shown to be a critical paracrine factor that maintains stem cell pluripotency in murine embryonic stem cells and human naïve stem cells while simultaneously inhibiting differentiation. We recently produced recombinant human LIF (rhLIF) in a rice-based protein expression system known as ExpressTec. (12) We described expression of rice-derived rhLIF and demonstrated its biological equivalency to E. coli-derived rhLIF in traditional and embryonic mouse stem cell systems. Here we describe the expression yield of rice-derived rhLIF and the scale up production capacity. We provide further evidence of the efficacy of rice-derived rhLIF in additional stem cell systems including human neural stem cells and mouse induced pluripotent stem (iPS) cells. The expression level, biological activity, and potential for production at commercial scale of rice-derived rhLIF provides a proof-of-principal for ExpressTec-derived proteins to produce regulatory-friendly, high performance, and dependable stem cell media.

Indexed as

AnimalsBiomarkersCell DifferentiationCodonEscherichia coliGene ExpressionGlycosylationHomeodomain ProteinsHumansInduced Pluripotent Stem CellsLeukemia Inhibitory FactorMiceNanog Homeobox ProteinNeural Stem CellsOctamer Transcription Factor-3OryzaBiomarkersCodonHomeodomain ProteinsLeukemia Inhibitory FactorNanog Homeobox ProteinNANOG protein, humanOctamer Transcription Factor-3POU5F1 protein, humanRecombinant Proteinsembryonic stem cellgrowth rateLIFNanogOct 4recombinant protein expression

Identifiers

PMID24776984
PMCPMC4101010
OpenAlexW2092554452

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.